- Home
- PDSB
as 04-25-2025 4:00pm EST
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 43.1M | IPO Year: | N/A |
| Target Price: | $10.00 | AVG Volume (30 days): | 275.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.85 - $4.42 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of PDS Biotechnology Corporation (PDSB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Freitag Gregory Gene | PDSB | Director | Feb 28 '25 | Buy | $1.66 | 15,060 | $24,999.60 | 61,213 | |
| Glover Stephen C. | PDSB | Director | Feb 28 '25 | Buy | $1.66 | 15,061 | $25,001.26 | 78,851 |
Latest PDS Biotechnology Corporation News
PDSB Breaking Stock News: Dive into PDSB Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
10 days ago
PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting
GlobeNewswire
18 days ago
PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
GuruFocus.com
a month ago
PDS Biotechnology Corp (PDSB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...
Thomson Reuters StreetEvents
a month ago
Q4 2024 PDS Biotechnology Corp Earnings Call
GlobeNewswire
a month ago
PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update
GlobeNewswire
a month ago
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference
Insider Monkey
a month ago
PDS Biotechnology (PDSB): Among the Penny Stocks With Huge Upside Potential According to Analysts
Compare PDSB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PDSB PDS Biotechnology Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.